secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001654954-26-002072
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics reports Q4/FY2025 loss; LEVEL study fully enrolled, topline Q3 2026
--------------------------------------------------------------------------------

- Achieved 230-patient randomization target in Phase 3 LEVEL study; topline data expected Q3 2026.
- Cash and equivalents $97.6M as of Dec 31, 2025; expected to fund operations through 2027.
- Full-year 2025 net loss $52.6M vs $17.6M in 2024; R&D spend $32.7M on trial expansion.
- Initiated global Phase 3 LEVEL-2 trial and open-label extension for TNX-103 (levosimendan) in PH-HFpEF.
- USPTO issued Notice of Allowance for subcutaneous levosimendan formulation in broad indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495426002072/0001654954-26-002072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495426002072/tennx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-26-002072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer